Citius Oncology CTOR
NASDAQ CTOR
$0.56 0.00 (-0.71%)
As of: Nov 11, 2026 · 3:59 PM EST

Citius Oncology (CTOR) Change in Receivables (2025 - 2026)

Updated

Citius Oncology's Change in Receivables was -$392,820 in fiscal Q3 2026 (quarter ended Jun 30, 2026).

Analysis

Citius Oncology (CTOR) Change in Receivables (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Receivables (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -188.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -312.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 108.00 Mn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -52.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Citius Oncology 60.42 Mn 30.00 Mn 1.00 Mn -392,820.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -392,820.00
Mar 31, 2026 -2.97 Mn
Dec 31, 2025 4.05 Mn
API Access

Citius Oncology Change in Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-receivables&ticker=CTOR&period=max&api_key=YOUR_API_KEY